Synthetic Control Arms in Clinical Trials

A synthetic control arm is constructed from external data rather than participants randomized concurrently in the same trial. Sources may include earlier clinical trials, registries, or real-world data. These approaches can be useful when randomization is difficult or ethically challenging, but comparison is vulnerable to bias. Patients in different datasets may differ in disease severity, eligibility, time period, standard of care, outcome measurement, or follow-up. FDA’s guidance for externally controlled trials advises sponsors to finalize the protocol, external control selection, and analytic approach before the trial begins. It emphasizes prespecified eligibility criteria, data sources, exposure definitions, clinically meaningful endpoints, missing-data plans, and bias minimization. Selecting a control dataset after outcomes are known can favor a desired result. The study must justify why the disease course and available data support an external comparison. AI may assist matching or weighting patients, but statistical adjustment cannot recover information that was never collected or eliminate unmeasured confounding. Sponsors should test comparability, examine overlap, conduct sensitivity analyses, and report limitations. A synthetic arm is not automatically equivalent to randomized evidence. Regulators and reviewers assess whether the design supports the specific inference being claimed. The protocol should explain why an external comparator is appropriate, which sources were considered, and what limitations could change the interpretation. If important prognostic factors cannot be measured comparably, a synthetic arm may give a misleading estimate even after statistical matching.